Premedication with 20 mg dexamethasone effectively prevents relapse of extensive skin rash associated with gemcitabine monotherapy

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 189-190

  Kanai, M ^a   Matsumoto, S ^a   Nishimura, T ^a   Matsumura, Y ^a   Hatano, E ^a   Mori, A ^a   Masui, T ^a   Kawaguchi, Y ^a   Nakamura, E ^a   Tada, S ^a   Kitano, T ^a   Ishiguro, H ^a   Yanagihara, K ^a   Chiba, T ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DEXAMETHASONE; FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; CASE REPORT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; LETTER; LIPOSARCOMA; MALE; PANCREAS CANCER; PRIORITY JOURNAL;

EID: 77949332675     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp513     Document Type: Letter

References (4)

1. Chen YM, Liu JM, Tsai CM et al. Maculopapular rashes secondary to gemcitabine injection for non-small-cell lung cancer. J Clin Oncol 1996; 14: 1743-1744.
2. Burris HAIII, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
3. Okada S, Ueno H, Okusaka T et al. Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001; 31: 7-12.
4. Mermershtain W, Cohen AD, Lazarev I et al. Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder. J Chemother 2003; 15: 510-511.